Diseases of the salivary gland: Tests of salivary gland function are at present unsatisfactory. We have looked to see if the saliva/plasma 1321 ratio might be abnormal in salivary gland disease (Mason et al. 1967) . Some patients we studied with Sjogren's syndrome did have low values (Fig 3) and these were the patients with the most severe radiological changes noted on sialography.
Summary
Significant quantities of iodide are cleared from the plasma by the salivary glands. The iodine in saliva is almost entirely in the inorganic form. Its concentration varies with flow rate and the plasma inorganic iodine (Pl1) level. Estimation of the salivary iodide may be of value in studies of the iodide trap, in iodine kinetic studies, in estimation of the PII and diagnostically in goitrous cretins with congenital inability of the thyroid to trap iodide. The saliva "311/PB'311 ratio is a poor test of thyroid function. Further work is required to clarify the role of salivary iodide estimation and isotope scanning in salivary gland disease (Harden et al. 1967 Fasting plasma tyrosine levels are known to be raised in hyperthyroidism and lowered in hypothyroidism. Rivlin et al. (1965) found that the plasma tyrosine level half an hour after a tyrosine load was most helpful in the diagnosis of thyrotoxicosis, whereas Malamos et al. (1965) , who only estimated fasting plasma tyrosine levels, found these to be higher than normal in all thyrotoxic patients studied. In neither study were the criteria for the selection of the control groups defined. In the validation of a test of thyroid function it is important to carry out the test in an unselected series of patients referred because of suspicion of the thyroid disorder. Patients who are found to be euthyroid by clinical assessment and by thyroid investigations other than that being validated can then be used as a control group for those found to be thyrotoxic. In this way patients with hyperthyroidism of all grades of severity are included and the test can be assessed in the clinical situation where it might subsequently be used. Plasma tyrosine levels were estimated by the method of Waalkes & Udenfriend (1957) . The oral tyrosine tolerance test was performed on an unselected consecutive group of patients referred to a medical outpatient clinic because hyperthyroidism was suspected. After an overnight fast a specimen of blood was obtained and the patient was given an oral dose of 1-tyrosine (50 mg per kg body weight) suspended in 40 ml of water. Further blood samples were taken 30 and 60 minutes afterwards. Measurement of halfand one-hour plasma tyrosine levels was performed after one-fifth and one-tenth dilution respectively. Because of this the analysis of all results was carried out after logarithmic conversion and the results converted back to normal figures for their presentation.
All patients had routine clinical assessment and tests of thyroid function including thyroidal six-hour 1311 uptake and serum protein-bound iodine. With these results the patients could be divided into two groups: Group I, the proven thyrotoxic, of whom there were 33; and Group II, the proven euthyroid, who were used as controls and of whom there were 25. The age and sex distribution in the two groups were similar, and in the event there was no difference in the fasting plasma tyrosine level related to either age or sex. Tyrosine tolerance tests were also performed on 8 patients referred with hypothyroidism. The mean level for euthyroid patients was 11.7 pg/mi, which agrees closely with the findings of other workers -12-2 pg/ml (Rivlin et al. 1965 ), 10-13 pg/ml (Waalkes & Udenfriend 1957 ) and 6-4 pmole/100 ml (Malamos et al. 1965) . The upper and lower 95% confidence limits for the control group of euthyroid patients is indicated by the broken lines in Figs 1, 2 and 3. In hypothyroidism the mean fasting level tended to be lower than normal confirming the findings of these workers but the values overlapped the normal range. In the thyrotoxic patients the mean level of 16-2 pg/ml was significantly higher than the euthyroid, but again there was overlap and 36% of the thyrotoxic patients had fasting plasma tyrosine levels within the normal range. Because of this considerable overlap we conclude that the fasting plasma tyrosine estimation is of little value in distinguishing thyrotoxic patients from patients referred with suspected thyrotoxicosis who are found to be euthyroid and are usually suffering from some psychiatric disorder. Fig 2 shows the plasma tyrosine levels half an hour after the tyrosine load. The values in the hyperthyroid group tended to be higher, and there was a statistically significant difference in the mean levels. Again there was considerable overlap and 35 % of values fell within the normal range. The metabolic disorder responsible for the abnormalities of tyrosine metabolism in hyperthyroidism is not fully understood. Fig 4 outlines the main pathways of tyrosine metabolism. Tyrosine is converted to p-hydroxyphenyl-pyruvic acid by the action of tyrosine a-ketoglutarate transaminase. Subsequent degradative steps involve oxidation via homogentisic acid, to fumaric acid and acetoacetic acid. The enzyme p-hydroxyphenyl pyruvate hydroxylase requires the presence of ascorbic acid to maintain full activity. Elevated plasma tyrosine in hyperthyroidism is unlikely to be due to a generalized disorder of amino-acid metabolism since glutamic acid is the only other amino acid to show increased levels (Melmon et al. 1964) . The abnormal tolerance is not due to increased absorption since abnormal tyrosine tolerance occurs after the intravenous administration of tyrosine to thyrotoxic patients (Rivlin et al. 1965 ). Increased formation of tyrosine is unlikely to be the cause as the activity of phenylalanine hydroxylase is not increased (Rivlin & Kaufman 1965) . Decreased degradation of tyrosine is most likely to account for the raised levels, but the picture is by no means clear. The activity of tyrosine transaminase was reported to be increased in the liver of rats rendered hyperthyroid (Rivlin et al. 1962 , Rivlin & Levine 1963 which should tend to reduce the plasma levels of tyrosine but Litwack (1957) showed that the activity of this enzyme is decreased in hyperthyroidism and that thyroid hormone inhibits tyrosine transaminase in vitro.
It is possible that the impaired hepatic function which is known to occur in some patients with thyrotoxicosis could be responsible for the decreased tyrosine tolerance since tyrosine metabolism is markedly affected by liver disease. Malamos et al. (1965) have claimed that the elevated fasting levels of plasma tyrosine in hyperthyroidism are due to a latent ascorbic acid deficiency. It is known that tyrosine tolerance is impaired in scurvy. They were able to correct the elevated levels in their thyrotoxic patients by the administration of ascorbic acid. This claim was investigated in two ways: (i) Detailed dietary histories were taken from most of the patients tested. None of the thyrotoxic patients was found to have a diet deficient in ascorbic acid, in fact one-half had a high or very high intake (more than 50 mg per day). (2) Ascorbic acid was administered to some of the patients, either in the low dosage of 25 mg b.d. for one week, or in a high dosage 1,500 mg daily for three days. Table 1 shows that there was no difference in the mean levels in either group after ascorbic acid. In the individual patient it is impossible to predict whether the fasting tyrosine level will go up or down, or stay the same (Fig 5) . We conclude that impaired tyrosine tolerance in thyrotoxic patients is unlikely to be due to ascorbic acid deficiency.
In summary, estimation of fasting plasma tyrosine levels and the performance of an oral tyrosine tolerance test is of no value in distinguishing the hypothyroid patient from normal. Fasting plasma tyrosine levels are raised in the majority of thyrotoxic patients and tyrosine tolerance is abnormal. The tyrosine tolerance test has little value as a routine test of thyroid function; oral administration of tyrosine increases the number of experimental variables and hence widens the range of values obtained. This is not an improvement upon the estimation of the fasting level alone. We have found that a fasting tyrosine level greater than 14-3 pg/ml is suggestive of thyrotoxicosis, but 36 % of patients will have values within the normal range which limits the usefulness of this estimation as a test of thyroid overactivity. There is an increasing body of evidence suggesting that the long-acting thyroid stimulator (LATS) originally discovered by Adams & Purves (1956) is the factor ultimately responsible for the excessive thyroid activity of patients suffering from thyrotoxicosis (Carneiro et al. 1966) . Interest in LATS has grown rapidly since it was established that this type of thyroid-stimulating activity is closely associated with the immunoglobulin G (IgG) fraction of the serum proteins and in many respects resembles an antibody (Dorrington & Munro 1966) .
The intravenous injection of serum containing LATS into mice prepared for the widely used McKenzie (1958) bioassay results in sustained stimulation of thyroid function which does not reach its maximum for ten to twelve hours. In contrast, the action of pituitary thyroid-stimulating hormone (TSH) is much briefer, reaching a peak two to three hours after intravenous injection. It is by these widely differing time-courses of action that TSH and LATS are distinguished in the McKenzie assay.
Adams (1960) and McKenzie (1961) have shown that the half-life of LATS in the circulation of assay animals is much longer than that of TSH, which probably accounts for the contrast in their duration of action.
It was, therefore, of great interest when the bioassay of Brown & Munro (1967) was established in this laboratory to compare the actions of these two thyroid stimulators in vitro, where the difference in half-lives would not apply.
Methods
The assay: The in vitro assay of Brown & Munro (1967) measures TSH by the discharge of 13L1 from pre-labelled mouse thyroids maintained in a shaker incubator at 350 C in modified Gey's fluid with 95 % oxygen, 5 % carbon dioxide as the gaseous phase. After a period on a diet of low iodine content, White Swiss mice were injected with 1311 intraperitoneally and two to three hours later their thyroids were quickly transferred to test tubes containing 1 ml of culture medium. Groups of 5 preparations were used for each solution tested. After sixteen hours' incubation control preparations (without any TSH added to the culture medium) released 10-150% of the thyroidal 131f into the surrounding medium. In the presence of TSH this release increased up to a maximum around 70 %.
Paper chromatography: On completion of the assay, the distribution of 1311 remaining in the glands and in the culture medium was measured separately by ascending paper chromatography on Whatman No. I paper in both butanol: 2 N acetic acid (1: 1) and butanol :ethanol: 05 N NH4OH (5: 1: 2). Carriers were invariably added; mouse thyroids were digested with pronase in phosphate buffer (0-2 M) at pH 7*5 for four hours at 35' C. After twenty hours the strips were dried and the radioactive spots located by an automatic recording chromatogram scanner (Nuclear Chicago 4 v7 Actigraph II Model 1032).
